Virology

Last updated: 2022 May 14
Total hit(s): 21
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Prevalence of antibodies to Sars-Cov-2 Spike protein at baseline was higher in participants who were prescribed 800mg molnupiravir compared to participants prescribed placebo. Reduction in viral load and reduction in time to negative test was significantly reduced in participants prescribed 800mg molnupiravir compared to all other participants. Strong biological evidence of using molnupiravir as oral drug to reduce uninterrupted viral replication has been provided in this study.
✍
 		34941423
(Sci Transl Med)
PMID
34941423
Date of Publishing: 2021 Dec 23
Title A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
Author(s) nameFischer WA 2nd, Eron JJ Jr et al.
Journal Sci Transl Med
Impact factor
11.64
Citation count: 24
Date of Entry 2022 May 14

A mammalian cell-based assay was used to identify the coronavirus 3CL protease/pro inhibitors that does not require the use of live virus which demonstrated the assays utility that were highly concordant with the results from live virus testing and identified a set of key structural features shared among broadly active 3CLpro inhibitors. The data suggested that the assay could be applicable to other protease families, thus, representing a general platform for viral protease inhibitor studies. Because of the assays breadth and ease of use, it is well suited to form the backbone of a forward-thinking pandemic preparedness strategy. This would not only be capable of addressing the current human coronaviral strains but also provide the biomedical community with a series of high-value chemical leads to perform additional focused chemical optimization. These compounds could be further checked whether they have undergone preclinical testing for human use.
✍
 		33910954
(J Virol)
PMID
33910954
Date of Publishing: 2021 Apr 28
Title Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity
Author(s) nameResnick SJ, Iketani S et al.
Journal J Virol
Impact factor
4.16
Citation count: 8
Date of Entry 2021 Aug 10

No significant reduction in viral load was observed from baseline to day 15 among different treatment group patients (Lopinavir/Ritonavir, IFN-ß-1a, Hydroxychloroquine, and control group ). Normalized SARS-CoV-2 viral loads were qualitatively and quantitatively assessed in Nasopharyngeal and lower respiratory specimens.
✍
 		Pre-print (medRXiv)
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name -
Impact factor
N/A
Date of Entry 2021 Jun 14

HCQ did not significantly reduce the viral load in patients. No differences in the viral load reduction between the two groups of patients were observed (HCQ and control group). Samples were tested for the detection of N1 and N2 targets (nucleoprotein gene) of the SARS-CoV-2. Samples with Ct values <40 were considered positive
✍
 		33111169
(Braz J Microbiol)
PMID
33111169
Date of Publishing: 2020 Dec
Title No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Author(s) nameFaíco-Filho KS, Conte DD et al.
Journal Braz J Microbiol
Impact factor
1.67
Citation count: 6

The combined treatment of Remdesivir and convalescent plasma therapy created an effective virological response for an immunocompromised patient who was previously struggling to control the viremia.
✍
 		33103195
(Clin Infect Dis)
PMID
33103195
Date of Publishing: 2020 Oct 26
Title Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19
Author(s) nameMalsy J, Veletzky L et al.
Journal Clin Infect Dis
Impact factor
7.71
Citation count: 20

Viral clearance within 14 days in the non-Arbidol group was lower than that of the Arbidol group. Table 4: Time to PCR negative in patients with or without Arbidol based on gender(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582420/table/Tab4/)
✍
 		33097047
(Virol J)
PMID
33097047
Date of Publishing: 2020 Oct 23
Title Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series
Author(s) nameGao W, Chen S et al.
Journal Virol J
Impact factor
2.45
Citation count: 8

No significant difference in the viral load reduction was observed between the treatment groups (HCQ and Control group). The Samples were tested for the detection of E-gene of SARS-CoV-2.
✍
 		33082342
(Nat Commun)
PMID
33082342
Date of Publishing: 2020 Oct 20
Title A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Author(s) nameLyngbakken MN, Berdal JE et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 41

Viral loads decreased over time in 3 of 4 patients after Remdesivir treatment. Patient 3 died due to multiple organ failures
✍
 		32418190
(Infection)
PMID
32418190
Date of Publishing: 2020 Oct
Title Early experience with remdesivir in SARS-CoV-2 pneumonia
Author(s) nameDurante-Mangoni E, Andini R et al.
Journal Infection
Impact factor
2.84
Citation count: 13

Viral loads decreased over time in 3 of 5 patients after Remdesivir treatment. But two patients died due to disease severity. Age of case 1: 31-year-old. Age of case 2: 80-year-old Age of case 3: 39-year-old Age of case 4: 76-year-old Age of case 5: 70-year-old
✍
 		32619764
(Int J Infect Dis)
PMID
32619764
Date of Publishing: 2020 Sep
Title Case report study of the first five COVID-19 patients treated with remdesivir in France
Author(s) nameDubert M, Visseaux B et al.
Journal Int J Infect Dis
Impact factor
3.42
Citation count: 14

This study reports that after 72 hours, 87.2% and 37.5% of patients showed negative SARS-CoV-2 conversion rates in the Convalescent plasma group and control group, respectively.
✍
 		32492084
(JAMA)
PMID
32492084
Date of Publishing: 2020 Aug 4
Title Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Author(s) nameLi L, Zhang W et al.
Journal JAMA
Impact factor
14.78
Citation count: 647

HCQ treated patients showed a significant reduction in viral load. The effect of HCQ increased when given in combination with Azithromycin. Among hydroxychloroquine-treated patients six patients received azithromycin
✍
 		32205204
(Int J Antimicrob Agents)
PMID
32205204
Date of Publishing: 2020 Jul
Title Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Author(s) nameGautret P, Lagier JC et al.
Journal Int J Antimicrob Agents
Impact factor
4.6
Citation count: 2374

This study compares the effect of convalescent plasma therapy against the control group on viral shedding and survival in COVID-19 patients with serious respiratory failure
✍
 		32348485
(J Infect Dis)
PMID
32348485
Date of Publishing: 2020 Jun 16
Title Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019
Author(s) nameZeng QL, Yu ZJ et al.
Journal J Infect Dis
Impact factor
4.73
Citation count: 176

4.4% of patients treated with hydroxychloroquine and azithromycin had a poor virological outcome (viral load was detectable after 10 days of treatment). 2 of 8 PVirO patients had a co-infection of bocavirus.
✍
 		32387409
(Travel Med Infect Dis)
PMID
32387409
Date of Publishing: 2020 May-Jun
Title Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Author(s) nameMillion M, Lagier JC et al.
Journal Travel Med Infect Dis
Impact factor
3.42
Citation count: 223

The mean baseline viral RNA loads were slightly higher in the Lopinavir-Ritonavir group than in the standard care group. But the percentage of patients with detectable viral RNA was similar in both groups. Samples were tested for the detection of E gene, RdRp gene, and N gene of SARS-CoV-2.
✍
 		32187464
(N Engl J Med)
PMID
32187464
Date of Publishing: 2020 May 7
Title A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
Author(s) nameCao B, Wang Y et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 2551

The viral load significantly decreased over time in the combination group (beta-1b, Lopinavir-Ritonavir, and ribavirin) than in the control group (Lopinavir-Ritonavir).
✍
 		32401715
(Lancet)
PMID
32401715
Date of Publishing: 2020 May 30
Title Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Author(s) nameHung IF, Lung KC et al.
Journal Lancet
Impact factor
43.38
Citation count: 739

Viral load decreased over time comparably in both groups (Remdesivir group and placebo group). The Samples were tested for the detection of E-gene, RNA-dependent RNA polymerase gene, and N-gene of SARS-CoV-2.
✍
 		32423584
(Lancet)
PMID
32423584
Date of Publishing: 2020 May 16
Title Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Author(s) nameWang Y, Zhang D et al.
Journal Lancet
Impact factor
43.38
Citation count: 1589

Critically ill, 5 COVID-19 patients were treated with the transfusion of "Convalescent- plasma" containing SARS-CoV-2 specific antibody. A significant reduction in viral load within 12 days of treatment was observed.
✍
 		32219428
(JAMA)
PMID
32219428
Date of Publishing: 2020 Apr 28
Title Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Author(s) nameShen C, Wang Z et al.
Journal JAMA
Impact factor
14.78
Citation count: 1141

COVID-19 patients were treated with Convalescent- plasma containing a high concentration of SARS-CoV-2 specific neutralizing antibodies (titers above 1:640). Serum SARS-CoV-2 RNA load disappeared within 3 to 6 days after CP therapy.
✍
 		32253318
(Proc Natl Acad Sci U S A)
PMID
32253318
Date of Publishing: 2020 Apr 28
Title Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Author(s) nameDuan K, Liu B et al.
Journal Proc Natl Acad Sci U S A
Impact factor
9.35
Citation count: 951

Compound 13b inhibits SARS-CoV-2 replication in human Calu-3 lung cells. The hydrophobic and bulky Boc group is necessary to cross the cellular membrane https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164518/figure/F1/
✍
 		32198291
(Science)
PMID
32198291
Date of Publishing: 2020 Apr 24
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D et al.
Journal Science
Impact factor
20.57
Citation count: 1159

Compound 13b inhibits SARS-CoV-2 replication in human Calu-3 lung cells. The hydrophobic and bulky Boc group is necessary to cross the cellular membrane https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164518/figure/F1/
✍
 		32198291
(Science)
PMID
32198291
Date of Publishing: 2020 Apr 24
Title Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors
Author(s) nameZhang L, Lin D et al.
Journal Science
Impact factor
20.57
Citation count: 1159

A rapid fall of viral load reported over time, with 83% negative at Day 7 and 93% at Day 8 after receiving a combination of the drug (Hydroxychloroquine and Azithromycin). Negative results for viral RNA detection were defined as those with a cycle threshold (Ct) value35
✍
 		32289548
(Travel Med Infect Dis)
PMID
32289548
Date of Publishing: 2020 Mar-Apr
Title Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Author(s) nameGautret P, Lagier JC et al.
Journal Travel Med Infect Dis
Impact factor
3.42
Citation count: 350